Timing of the Initiation of Bisphosphonates After Surgery for Fracture Healing: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2014 Oct 1

PMID 25266485

Citations 32

Authors

Y-T Li

H-F Cai

Z-L Zhang

Affiliations

Soon will be listed here.

Abstract

Summary: We performed a systematic review and meta-analysis of randomized clinical trials. Early administration of bisphosphonates (BPs) after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

Introduction: Bisphosphonates (BPs) are widely used in the prophylaxis and treatment of osteoporosis. However, early administration of BPs after surgical repair of a fracture may limit the reserve capacity of bone to heal. The aim of this review and meta-analysis was to analyze the benefits and adverse effects of early administration of BPs and give recommendations regarding when BPs should be utilized.

Methods: We identified randomized controlled trials comparing the early administration of BPs to placebo, delayed BP treatment, or no therapy in adult patients after surgery. The search was performed in PubMed, the Cochrane Library, and Embase.

Results: Ten studies with 2888 patients were included. Four trials used alendronate, three trials used zoledronic, two trials used risedronate, and one trial used etidronate. Early administration of BPs was considered less than 3 months after surgery. Patients treated with BP therapy had no significant differences in radiological fracture healing times compared with patients in the control group (mean difference [MD] 0.47, 95% confidence interval [CI] -2.75 to 3.69). There were also no significant differences in the rate of delay or nonunion of fracture healing (odds ratio [OR] 0.98, 95% CI 0.64 to 1.50). However, the bone mineral density (BMD) of total hips did significantly improve after 12 months of treatment with BPs. And most bone turnover markers of patients in the study group were significantly decreased.

Conclusions: Early administration of BPs after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, according to the changes in BMD and bone turnover markers, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

Citing Articles

[Influencing fracture healing by specific osteoporosis medications].

Stumpf U, Schmidmaier R, Taipaleenmaki H, Bocker W, Kurth A, Hesse E Z Rheumatol. 2025; 84(2):107-112.

PMID: 39806104 DOI: 10.1007/s00393-024-01610-y.

The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials.

Zeng Y, Yang Y, Wang J, Meng G Osteoporos Int. 2024; 35(11):1897-1907.

PMID: 39115687 PMC: 11499321. DOI: 10.1007/s00198-024-07191-5.

Taking care of inpatients with fragility hip fractures: the hip-padua osteosarcopenia (Hip-POS) fracture liaison service model.

Arcidiacono G, Ceolin C, Sella S, Camozzi V, Bertocco A, Torres M J Endocrinol Invest. 2024; 48(1):99-108.

PMID: 38971949 PMC: 11729073. DOI: 10.1007/s40618-024-02425-z.

Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.

Chandran M, Akesson K, Javaid M, Harvey N, Blank R, Brandi M Osteoporos Int. 2024; 35(8):1337-1358.

PMID: 38587674 PMC: 11282157. DOI: 10.1007/s00198-024-07059-8.

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture.

Johansen A, Sahota O, Dockery F, Black A, MacLullich A, Javaid M Age Ageing. 2023; 52(9).

PMID: 37776543 PMC: 10542103. DOI: 10.1093/ageing/afad172.

References

Odvina C, Levy S, Rao S, Zerwekh J, Rao D . Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2009; 72(2):161-8. DOI: 10.1111/j.1365-2265.2009.03581.x. View

Coates P . Bone turnover markers. Aust Fam Physician. 2013; 42(5):285-7. View

Adachi J, Lyles K, Colon-Emeric C, Boonen S, Pieper C, Mautalen C . Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. 2011; 22(9):2539-49. DOI: 10.1007/s00198-010-1514-9. View

Adachi J, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L . Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial. Calcif Tissue Int. 2011; 89(6):427-33. PMC: 3215881. DOI: 10.1007/s00223-011-9543-8. View

Grady M, Watson J, Cannada L . Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics. 2012; 35(6):e991-5. DOI: 10.3928/01477447-20120525-51. View

Colon-Emeric C, Lyles K, Su G, Pieper C, Magaziner J, Adachi J . Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int. 2011; 88(5):425-31. DOI: 10.1007/s00223-011-9474-4. View

Kim T, Ha Y, Kang B, Lee Y, Koo K . Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?. J Bone Joint Surg Br. 2012; 94(7):956-60. DOI: 10.1302/0301-620X.94B7.29079. View

Li H, Xie H, Liu W, Hu R, Huang B, Tan Y . A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest. 2009; 119(12):3666-77. PMC: 2786801. DOI: 10.1172/JCI39832. View

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View

10.

Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S . Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am. 2007; 89(1):96-101. DOI: 10.2106/JBJS.F.00484. View

11.

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

12.

Li C, Wang H, Li X, Zhou X, Dong J . The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien). 2012; 154(4):731-8. DOI: 10.1007/s00701-012-1283-7. View

13.

Goodship A, WALKER P, McNally D, Chambers T, Green J . Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol. 1994; 5 Suppl 7:S53-5. View

14.

Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T . Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J. 2013; 95-B(11):1544-50. DOI: 10.1302/0301-620X.95B11.31652. View

15.

Guo L, Zhao R, Wu Y . The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp Hematol. 2011; 39(6):608-16. DOI: 10.1016/j.exphem.2011.01.011. View

16.

Giusti A, Hamdy N, Papapoulos S . Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone. 2010; 47(2):169-80. DOI: 10.1016/j.bone.2010.05.019. View

17.

Rozental T, Vazquez M, Chacko A, Ayogu N, Bouxsein M . Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am. 2009; 34(4):595-602. DOI: 10.1016/j.jhsa.2008.12.011. View

18.

Bauss F, Schenk R, Hort S, Muller-Beckmann B, Sponer G . New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods. 2004; 50(1):25-34. DOI: 10.1016/j.vascn.2003.11.003. View

19.

Colon-Emeric C, Caminis J, Suh T, Pieper C, Janning C, Magaziner J . The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin. 2004; 20(6):903-10. DOI: 10.1185/030079904125003683. View

20.

Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J . Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil. 2004; 83(4):298-303. DOI: 10.1097/01.phm.0000122877.28631.23. View